SCHEMBL1914743

SCHEMBL1914743

CCCCCCCCCCCCCCCC(=O)CC(=O)CCCCCCCCCCCC

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.71
KMT2A Q03164 2/20 0.65
MAPT P10636 1/20 0.65
CES2 O00748 4/20 0.62
CES1 P23141 4/20 0.62
GPR84 Q9NQS5 7/20 0.59
PPARG P37231 7/20 0.59
PPARD Q03181 7/20 0.59
PPARA Q07869 7/20 0.59
HDAC11 Q96DB2 5/20 0.59
TSHR P16473 4/20 0.59
PTPN1 P18031 3/20 0.59
ALDH1A1 P00352 2/20 0.59
TLR2 O60603 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
FABP4 P15090 2/20 0.59
SLC22A6 Q4U2R8 1/20 0.59
SLC22A8 Q8TCC7 1/20 0.59
MEN1 O00255 1/20 0.59
ESR1 P03372 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3308042 1.00 HAO1 (0.71) HAO1KMT2AMAPTCES2CES1
SCHEMBL3051705 1.00 HAO1 (0.71) HAO1KMT2AMAPTCES2CES1
SCHEMBL11672548 1.00 HAO1 (0.71) HAO1KMT2AMAPTCES2CES1
SCHEMBL11673566 1.00 HAO1 (0.71) HAO1KMT2AMAPTCES2CES1
SCHEMBL11673555 1.00 HAO1 (0.71) HAO1KMT2AMAPTCES2CES1
SCHEMBL7760601 1.00 HAO1 (0.71) HAO1KMT2AMAPTCES2CES1
SCHEMBL23437862 1.00 HAO1 (0.71) HAO1KMT2AMAPTCES2CES1
SCHEMBL11673647 1.00 HAO1 (0.71) HAO1KMT2AMAPTCES2CES1
SCHEMBL15941224 1.00 HAO1 (0.71) HAO1KMT2AMAPTCES2CES1
SCHEMBL7757516 1.00 HAO1 (0.71) HAO1KMT2AMAPTCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114729100-B Blocked polyisocyanate crosslinking agent, process for producing the same and coating composition comprising the same 巴斯夫涂料有限公司 2024-04-16 CN claimed
CN-114288422-B Liposome for degrading target protein in chemical targeting manner and preparation method thereof 陕西科技大学 2023-04-28 CN claimed
CN-112773766-B Liposome delivery system for tumor treatment and preparation method and application thereof 暨南大学 2022-10-18 CN claimed
CN-114729100-A Blocked polyisocyanate crosslinkers, process for their preparation and coating compositions comprising the crosslinkers 巴斯夫涂料有限公司 2022-07-08 CN claimed
CN-114288422-A Liposome for chemically targeted degradation of target protein and preparation method thereof 陕西科技大学 2022-04-08 CN claimed
US-11260068-B2 Long-circulating liposome modified with c(RGD-ACP-K) BEIJING GREATSUN BTO-PHARM. TECH. CO., LTD (CN) 2022-03-01 US claimed
CN-113975244-A Bionic magnetic targeting cationic liposome and preparation method and application thereof 上海交通大学医学院附属第九人民医院 2022-01-28 CN claimed
CN-112773766-A Liposome delivery system for tumor treatment and preparation method and application thereof 暨南大学 2021-05-11 CN claimed
WO-2020257260-A1 FORMULATION OF PEPTIDE LOADED LIPOSOMES AND RELATED APPLICATIONS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2020-12-24 WO claimed
CN-108926719-B Long-circulating liposomes modified with c (RGD-ACP-K) 北京格瑞特森生物医药科技有限公司 2020-09-01 CN claimed
US-20200197424-A1 LONG-CIRCULATING LIPOSOME MODIFIED WITH C(RGD-ACP-K) BEIJING GREATSUN BIO-PHARM. TECH. CO., LTD (CN) 2020-06-25 US claimed
EP-3632413-A1 LONG-CIRCULATING LIPOSOME MODIFIED WITH C(RGD-ACP-K) Beijing Greatsun Bio-pharm. Tech. Co., Ltd (CN) 2020-04-08 EP claimed
US-20240327291-A1 MULTIVALENT MANGANESE OXIDE FILLER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF UNIV CHONGQING (CN) 2024-10-03 US disclosed
CN-114729100-B Blocked polyisocyanate crosslinking agent, process for producing the same and coating composition comprising the same 巴斯夫涂料有限公司 2024-04-16 CN disclosed
EP-3473256-B1 INTRATUMORAL VEIN FORMATION PROMOTER UNIV OSAKA (JP) 2023-12-06 EP disclosed
CN-117100644-A Semitransparent to transparent aqueous solution containing sphingosine and non-salt derivatives and preparation method thereof 中妆美科(合肥)新材料技术有限公司 2023-11-24 CN disclosed
WO-2018052835-A1 COMPOSITIONS COMPRISING ANTISENSE-ENCODED ERYTHROPOIETIN RECEPTOR AND USE THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-03-22 WO disclosed
WO-2015021465-A2 PROTEIN ENGINEERED SYSTEMS FOR DELIVERY OF MOLECULES NEW YORK UNIVERSITY (US) 2015-02-12 WO disclosed
EP-2516010-A2 LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM Novartis AG (CH) 2012-10-31 EP disclosed
WO-2011076807-A2 LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM NOVARTIS AG (CH) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200197424-A1 LONG-CIRCULATING LIPOSOME MODIFIED WITH C(RGD-ACP-K) VEGFA, DCK, ACP1 HAO1 4243/4885KMT2A 2397/4885MAPT 4073/4885
US-11260068-B2 Long-circulating liposome modified with c(RGD-ACP-K) VEGFA, DCK, ACP1 HAO1 4243/4885KMT2A 2397/4885MAPT 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.